ArticleContact dermatitis2026
Patch Testing in Individuals With Diabetes Using Medical Devices. Part 2-Contact Allergy to Medical Device Allergens and New Patch Test Recommendations.
Article in Contact dermatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patch Testing in Individuals With Diabetes Using Medical Devices. Part 1-Contact Allergy to Baseline Series Allergens.Contact dermatitis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPrevious studies on contact allergy to diabetes medical devices (MDs) are based on patients referred for patch testing due to suspected allergic contact dermatitis.
objectivesTo present real-world data on contact allergy to MD allergens among diabetes MD users. To suggest a MD patch test series.
methodsAdults with type 1 diabetes using diabetes MDs followed up at two endocrinology departments were invited to be patch tested with a novel MD patch test series.
resultsOf the 204 participants (114 with skin rash to diabetes MDs, 90 without), 16.2% were positive to allergens found in diabetes MDs. The prevalence was significantly higher in those with skin rash to diabetes MDs versus without (28.1% vs. 1.1%; adjusted p-value < 0.001). For allergens found in diabetes MDs, the highest contact allergy rates were seen to isobornyl acrylate (10.3%), N,N-dimethylacrylamide (4.9%), 2-hydroxyethyl acrylate (3.4%), and dicyclohexylmethane-4,4'-diisocyanate (2.9%).
conclusionsAmong diabetes MD users, the prevalence of contact allergy to MD allergens was remarkably high. 2-hydroxyethyl acrylate has not previously been reported as a culprit allergen in diabetes MDs, which underlines the importance of repeated chemical analyses and continuous update of the MD series. A better prevention of MD-related contact allergies is called for.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.